Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus carboplatin and paclitaxel for metastatic or recurrent thymic carcinoma
jRCT2031220144Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, carboplatin and paclitaxel in thymic carcinoma (TC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Objective Response Rate. Started Jun 2022; status: completed.
02
Drugs
atezolizumabcarboplatinpaclitaxel
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on jRCT2031220144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220144.